[Treatment of premenopausal patients with advanced or recurrent breast cancer by chemical ablation].
OBJECTIVE
To evaluate the clinical efficacy and safety of luteinizing hormone releasing hormone (LH-RH) analog in premenopausal patients with advanced or recurrent breast cancer.


METHODS
LH-RH analog (enantone 3.75 mg/2 ml) were administered to 28 premenopausal patients with advanced recurrent breast cancer and its efficacy and side effect were observed.


RESULTS
The response rate (complete response and partial response) was 42.9%, and after 8 weeks of treatment, the plasma estrogen in all patients decreased to the level of postmenopause. No major adverse events were observed.


CONCLUSIONS
LH-RH analog is effective and safe for premenopausal breast cancer with low adverse reaction and its administration method is easy.
Sun
Qiang
Q
Department of Surgery, PUMC Hospital, CAMS, PUMC, Beijing 100730, China. sunq63@sohu.com
Huang
Han-yuan
HY
Zhou
Yi-dong
YD
Mao
Feng
F
Yang
Yue-qing
YQ
Xing
Ying
Y
D000328:Adult; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D004967:Estrogens / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D017697:Premenopause
D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D016729:Leuprolide